Relay Therapeutics Inc (NASDAQ:RLAY) price on Thursday, May 01, fall -1.20% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.29.
A look at the stock’s price movement, the close in the last trading session was $3.33, moving within a range at $3.22 and $3.355. The beta value (5-Year monthly) was 1.703. Turning to its 52-week performance, $10.72 and $1.77 were the 52-week high and 52-week low respectively. Overall, RLAY moved 33.20% over the past month.
Relay Therapeutics Inc’s market cap currently stands at around $560.91 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-25.
The average forecast suggests down to a -99.89% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 3.87M, representing a -61.36% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RLAY is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 5 recommend RLAY as a Buy and 1 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RLAY’s current price about 21.69% and 7.59% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 59.88, while 7-day volatility ratio is 8.38% and 10.65% in the 30-day chart. Further, Relay Therapeutics Inc (RLAY) has a beta value of 1.65, and an average true range (ATR) of 0.26. Analysts have given the company’s stock an average 52-week price target of $19, forecast between a low of $16 and high of $25. Looking at the price targets, the low is -386.32% off current price level while to achieve the yearly target high, price needs to move -659.88%. Nonetheless, investors will most likely welcome a -477.51% jump to $19 which is the analysts’ median price.
If we refocus on Relay Therapeutics Inc (NASDAQ:RLAY), historical trading data shows that trading volumes averaged 2.08 over the past 10 days and 2.32 million over the past 3 months. The company’s latest data on shares outstanding shows there are 167.76 million shares.
The 24.63% of Relay Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 79.61% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 18.36 million on 2025-04-15, giving us a short ratio of 6.02. The data shows that as of 2025-04-15 short interest in Relay Therapeutics Inc (RLAY) stood at 1310.0000000000002 of shares outstanding, with shares short falling to 19.12 million registered in 2025-03-14. Current price change has pushed the stock -20.15% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RLAY stock continues to rise going into the next quarter.
